摘要
药理遗传学研究基于应用统计学去评估描述自然变化的基因数据,以响应药物和疫苗等药物治疗学。一开始,药理遗传学研究以候选基因法为基础,专门关注与单个基因的变异有关的疗效或不良反应。这个假设驱动方法要求研究者必须有调查该基因或基因组的先验知识。根据合理的设计,药理遗传学研究的重点通常是药物代谢酶、药物转运蛋白和药物靶点。随着技术的发展,药理遗传学研究转换到自由假设探索,其中整个基因组的遗传标记可以在大的规模、人口基数、全基因组关联研究(GWAS)中测定。这使得新的遗传标记物的识别、治疗目标、以及基因-基因交互作用分析可能揭示药物活性的分子机制。最终的挑战在于利用基因药物与建立基于个体基因型的计量算法的关联,这将指导并确保医生开出正确剂量的正确药物,消除首次试错和不良反应。此文章将综述数据科学在药理效果的遗传分析中的的基本概念和应用。
关键词: 生物信息学,数据科学,遗传药理学,基因测试学,统计学。
Current Molecular Medicine
Title:Data Science Approaches to Pharmacogenetics
Volume: 14 Issue: 7
Author(s): N.M. Penrod and J.H. Moore
Affiliation:
关键词: 生物信息学,数据科学,遗传药理学,基因测试学,统计学。
摘要: Pharmacogenetic studies rely on applied statistics to evaluate genetic data describing natural variation in response to pharmacotherapeutics such as drugs and vaccines. In the beginning, these studies were based on candidate gene approaches that specifically focused on efficacy or adverse events correlated with variants of single genes. This hypothesis driven method required the researcher to have a priori knowledge of which genes or gene sets to investigate. According to rational design, the focus of these studies has been on drug metabolizing enzymes, drug transporters, and drug targets. As technology has progressed, these studies have transitioned to hypothesis-free explorations where markers across the entire genome can be measured in large scale, population based, genome-wide association studies (GWAS). This enables identification of novel genetic biomarkers, therapeutic targets, and analysis of gene-gene interactions, which may reveal molecular mechanisms of drug activities. Ultimately, the challenge is to utilize gene-drug associations to create dosing algorithms based individual genotypes, which will guide physicians and ensure they prescribe the correct dose of the correct drug the first time eliminating trial-and-error and adverse events. We review here basic concepts and applications of data science to the genetic analysis of pharmacologic outcomes.
Export Options
About this article
Cite this article as:
Penrod N.M. and Moore J.H., Data Science Approaches to Pharmacogenetics, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811112438
DOI https://dx.doi.org/10.2174/1566524014666140811112438 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Diabetes Beyond Insulin: Review of New Drugs for Treatment of Diabetes Mellitus
Current Drug Discovery Technologies Antidiabetic Activity of Dihydropyrimidine Scaffolds and Structural Insight by Single Crystal X-ray Studies
Medicinal Chemistry Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy
Current Drug Targets Inflammatory Cytokines and Atherosclerosis Possible Application for the Gene Therapy
Vascular Disease Prevention (Discontinued) Vasomotor Effects of Iodinated Contrast Media: Just Side Effects?
Current Vascular Pharmacology The Role of STAT 3 in Tissue Fibrosis
Current Chemical Biology Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews